RESUMEN
BACKGROUND: Vitamin K has long been regarded as a procoagulant drug by physicians, and concerns have been raised with regard to its effects on hemostasis. Although many studies have shown that vitamin K supplementation is safe for thrombotic events, the effect of vitamin K supplementation on the activities of vitamin K dependent procoagulation factors in healthy individuals is not available. OBJECTIVES: This study aimed to investigate whether vitamin K2 supplementation at recommended doses affects the activity of vitamin K dependent procoagulation factors in healthy individuals without any anticoagulation treatment. DESIGN: Forty healthy volunteers between 25 and 40âyears of age were recruited. Menaquinone-7 (MK-7) was administrated at 90âµg for 30âdays. Prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and blood coagulation factors II, VII, IX, and X activities and Protein induced by vitamin K absence or antagonist-II (PIVKA-II) were measured on days 0 and 30 after MK-7 administration. RESULTS: PT, APTT, and TT showed no significant differences on day 30 when compared with baseline. The activities of coagulation factors II, VII, IX, and X on day 30 showed no significant differences with those at baseline. PIVKA-II levels were unchanged after 30âdays of MK-7 supplementation. CONCLUSIONS: MK-7 supplementation at recommended dosage does not affect vitamin K-dependent coagulation factors' coagulation activity, and does not enhance the carboxylation of prothrombin in healthy individuals. This indicated that MK-7 administration does not alter hemostatic balance in healthy populations without anticoagulation treatment.
Asunto(s)
Factores de Coagulación Sanguínea/efectos de los fármacos , Suplementos Dietéticos/normas , Vitamina K 2/farmacología , Adulto , Antifibrinolíticos/farmacología , Antifibrinolíticos/uso terapéutico , Factores de Coagulación Sanguínea/análisis , Suplementos Dietéticos/estadística & datos numéricos , Factor IX/análisis , Factor IX/efectos de los fármacos , Factor VII/análisis , Factor VII/efectos de los fármacos , Factor X/análisis , Factor X/efectos de los fármacos , Femenino , Voluntarios Sanos/estadística & datos numéricos , Humanos , Masculino , Tiempo de Tromboplastina Parcial/métodos , Tiempo de Tromboplastina Parcial/estadística & datos numéricos , Protrombina/análisis , Protrombina/efectos de los fármacos , Tiempo de Protrombina/métodos , Tiempo de Protrombina/estadística & datos numéricos , Tiempo de Trombina/métodos , Tiempo de Trombina/estadística & datos numéricos , Vitamina K 2/uso terapéuticoRESUMEN
Direct oral anticoagulants (DOACs) can be quantified using methods that can be performed in any clinical or research laboratory using manual or automated instrument platforms. Dabigatran etexilate, the oral direct thrombin inhibitor, can be quantified by drug-calibrated clot or chromogenic-based assays using either thrombin or ecarin as substrates. Oral direct anti-Xa inhibitors, such as rivaroxaban, apixaban, and edoxaban, can be quantified with drug-calibrated anti-Xa kits or reagents as typically used for measuring heparins (unfractionated, low molecular weight, or pentasaccharides).
Asunto(s)
Antitrombinas/sangre , Antitrombinas/uso terapéutico , Monitoreo de Drogas/métodos , Inhibidores del Factor Xa/sangre , Inhibidores del Factor Xa/uso terapéutico , Tiempo de Trombina/métodos , Administración Oral , Antitrombinas/administración & dosificación , Coagulación Sanguínea/efectos de los fármacos , Dabigatrán/administración & dosificación , Dabigatrán/sangre , Dabigatrán/uso terapéutico , Endopeptidasas/administración & dosificación , Endopeptidasas/sangre , Endopeptidasas/uso terapéutico , Inhibidores del Factor Xa/administración & dosificación , Fibrinolíticos/administración & dosificación , Fibrinolíticos/sangre , Fibrinolíticos/uso terapéutico , Humanos , Pirazoles/administración & dosificación , Pirazoles/sangre , Pirazoles/uso terapéutico , Piridinas/administración & dosificación , Piridinas/sangre , Piridinas/uso terapéutico , Piridonas/administración & dosificación , Piridonas/sangre , Piridonas/uso terapéutico , Rivaroxabán/administración & dosificación , Rivaroxabán/sangre , Rivaroxabán/uso terapéutico , Tiazoles/administración & dosificación , Tiazoles/sangre , Tiazoles/uso terapéutico , Tromboembolia Venosa/sangre , Tromboembolia Venosa/tratamiento farmacológicoRESUMEN
BACKGROUND: Current use of prescribed or over the counter non-steroidal anti-inflammatory drugs (NSAIDs) for pain and osteoarthritis (OA) have untoward gastrointestinal and cardiovascular related side effects, as a result the need for a safe and effective alternative has become unequivocally crucial. METHOD: A randomized, double blind, placebo and active controlled pilot study of a novel dual pathway, COX1/2 and LOX, inhibitor anti-inflammatory agent of botanical origin, UP446 was conducted. Sixty subjects (age 40-75) with symptomatic OA of the hip or knee were assigned to 4 treatment groups (n = 15); Group A0 (Placebo, CMC capsule), Group A1 (UP446 250 mg/day), Group A2 (UP446 500 mg/day) and Group A3 (Celecoxib, 200 mg/day). MOS-SF-36 and Western Ontario and McMaster University Osteoarthritis Index (WOMAC) data were collected at baseline and after 30, 60 and 90 days of treatment as a measure of efficacy. Erythrocyte sedimentation rate, C-reactive protein, plasma thrombin time (PTT), fructosamine, Hematology, clinical chemistry and fecal occult blood were monitored for safety. RESULTS: Statistically significant decrease in WOMAC pain score were observed for Group A1 at day 90, Group A2 at 30 and 90 days and Group A3 at 60 and 90 days. Statistically significant decrease in WOMAC stiffness score were observed for Group A1 and Group A2 at 30, 60 and 90 days; but not for Group A0 and Group A3. The mean change in WOMAC functional impairment scores were statistically significant for Group A1 and Group A2 respectively at 30 days (p = 0.006 and p = 0.006), at 60 days (p = 0.016 and p = 0.002) and at 90 days (p = 0.018 and p = 0.002), these changes were not significant for Group A0 and Group A3. Based on MOS -SF-36 questionnaires, statistically significant improvements in physical function, endurance and mental health scores were observed for all active treatment groups compared to placebo. No significant changes suggestive of toxicity in routine hematologies, serum chemistries, liver enzymes or PTT were noted in any of the treatment groups. CONCLUSION: Based on current findings UP446 is safe and efficacious alternative to established anti-inflammatory medications for alleviating OA symptoms as measured by the WOMAC Index.